Table 5. Therapeutic details of ongoing RCTs on hyperthermic intraperitoneal chemotherapy (HIPEC) application.
| Principle Investigator Indication | Acronym | Randomization | Inclusion criteria | Planned Nr of patients | cytotoxic drug | Dosage, mg/m2 |
Volume [liters] | Concentration [mg/L] | HIPEC duration [min] | HIPEC [°C] | HIPEC technique |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Ongoing RCTs | |||||||||||
| Rau NCT02158988 | GASTRIPEC | CRS ± HIPEC | PM | 180 | MMC | 15 | 5 | 5.4 | 60 | 42–43 | Open or closed |
| CIS | 75 | 27.2 | |||||||||
| Glehen NCT01882933 | GASTRICHIP | Surgery ± HIPEC | T4 or Cyto pos | 367 | Oxaliplatin | 250 | 2 L/m2 | 125 | 30 | 42–43 | Open or closed |
| 50 | |||||||||||
| van Sandick NCT03348150 | PERISCOPE II | CRS + HIPEC vs. systemic chemo | Cyto pos or PM (PCI<7) | 106 | Oxaliplatin | 460 | n.a. | n.a. | 30 | 42 | Open |
| DOC | 50 | 90 | 37 | ||||||||
| Cui NCT02356276 | HIPEC-01 | Surgery ± HIPEC (2 times) | cT3-T4 | 584 | PTX | 1st 75 | 3–4 | 30–40 | 60 | 43 | n.a. |
| 2nd | 40–53.3 | ||||||||||
| NCT02528110 | n.a. | Surgery ± HIPEC | cT3-T4 | 100 | PTX | 75 | 3–4 | 30–40 | 60 | 43 | n.a. |
| 5-FU | 15 | 6–8 | |||||||||
HIPEC, hyperthermic intraperitoneal chemotherapy; Cyto pos, positive cytology; PM, peritoneal metastasis; CIS, cisplatin; MMC, mitomycin C; n.a., not available; DOC, docetaxel; PTX, paclitaxel; 5-FU, Fluorouracil.